<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589537</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-NCRI-TRISST-TE24</org_study_id>
    <secondary_id>CDR0000574037</secondary_id>
    <secondary_id>EU-20771</secondary_id>
    <secondary_id>ISRCTN65987321</secondary_id>
    <nct_id>NCT00589537</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle</brief_title>
  <official_title>Trial of Imaging and Schedule in Seminoma Testis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imaging procedures, such as MRI and CT scan, may find recurrent cancer. It is not
      yet known which MRI or CT scan schedule is more effective in finding recurrent cancer.

      PURPOSE: This randomized phase III trial is comparing four different MRI and CT scan
      schedules in patients with stage I seminoma of the testicle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To assess whether a reduced computed tomography (CT) schedule or magnetic resonance
           imaging (MRI) could be used as safe and effective alternatives to standard CT-based
           surveillance in the management of patients with stage I seminoma of the testis.

      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 4 surveillance arms.

        -  Arm I: Patients undergo computed tomography (CT) scan of the abdomen/retroperitoneum* at
           6, 12, 18, 24, 36, 48, and 60 months in the absence of disease progression.

        -  Arm II: Patients undergo CT scan of the abdomen/retroperitoneum* at 6, 18, and 36 months
           in the absence of disease progression.

        -  Arm III: Patients undergo magnetic resonance imaging (MRI) of the
           abdomen/retroperitoneum* at 6, 12, 18, 24, 36, 48, and 60 months in the absence of
           disease progression.

        -  Arm IV: Patients undergo MRI of the abdomen/retroperitoneum* at 6, 18, and 36 months in
           the absence of disease progression.

      NOTE: *Patients with a history of ipsilateral inguino-scrotal surgery also undergo imaging of
      the pelvis.

      Patients complete questionnaires at baseline and periodically during study to assess
      health-related quality of life; utilization and cost of healthcare services (including the
      cost of CT- or MRI-based surveillance and the management of any recurrence); and
      acceptability of allocated scanning schedule.

      Patients are followed every 3 months for 2 years, every 4 months for 1 year, and then every 6
      months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients relapsing with Royal Marsden Hospital stage IIC or greater disease</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in mean abdominal mass size at relapse between computed tomography (CT) scan and magnetic resonance imaging (MRI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on surveillance before detection of relapse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective identification of first modality to detect relapse (patient symptom, clinical examination, tumor marker, chest x-ray, cross-sectional image)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of relapse according to International Germ Cell Cancer Collaborative Group classification</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective evaluation of prognostic factors for relapse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of false positive MRIs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource use and costs</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Testicular Germ Cell Tumor</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed seminoma of the testis

               -  Stage I disease, as determined by clinical examination and CT scan of the chest,
                  abdomen, and pelvis

          -  No evidence of any non-seminoma germ cell tumor elements

          -  Has undergone orchidectomy within the past 8 weeks

               -  Normal serum alpha-fetoprotein pre-orchidectomy and at study randomization

               -  Normal serum beta human chorionic gonadotrophin at study randomization (may have
                  been elevated pre-orchidectomy)

          -  Not planning to undergo adjuvant therapy

        PATIENT CHARACTERISTICS:

          -  Able to attend regular surveillance

          -  No other malignancy within the past 10 years expect successfully treated nonmelanoma
             skin cancer

          -  No contraindication to MRI (i.e., ferrous metal implants of any type, cardiac
             pacemaker or defibrillator, or history of injury by metal fragments)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnathan Joffe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Huddersfield Royal Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>England</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Geldart</last_name>
      <phone>44-1202-726-088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sussex Cancer Centre at Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>England</state>
        <zip>BN2 5BF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bloomfield, MD</last_name>
      <phone>44-1273-696-955 ext. 7686</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Braybrooke, MD</last_name>
      <phone>44-117-928-2418</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Williams, MD</last_name>
      <phone>44-122-321-7020</phone>
      <email>michael.williams@addenbrookes.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Oncology Centre at Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <state>England</state>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.R. Owen, MD</last_name>
      <phone>44-84-5422-4021</phone>
      <email>roger.owen@glos.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield, West Yorks</city>
        <state>England</state>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnathan Joffe, MD</last_name>
      <phone>44-1484-342-150</phone>
      <email>jk.joffe@cht.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-113-206-6400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Benghiat, MD</last_name>
      <phone>44-116-258-5081</phone>
      <email>albert.benghiat@uhl-tr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lincoln County Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>England</state>
        <zip>LN2 5QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiagarajan Sreenivasant</last_name>
      <phone>44-1522-572-203</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Meyer, MD, BSc, MRCP, PhD</last_name>
      <phone>44-207-679-6731</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Savage, MD</last_name>
      <phone>44-20-8846-1419</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen J. Harland, MD</last_name>
      <phone>44-20-7380-9041</phone>
      <email>stephen.harland@uclh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Kent Oncology Centre at Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1622-729-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Logue</last_name>
      <phone>44-161-446-3407</phone>
      <email>john.logue@christie-tr.nwest.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Rathmell, MD</last_name>
      <phone>44-1642-854-750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Treatment at Newcastle General Hospital</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhona McMenemin</last_name>
      <phone>44-191-256-3588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital</name>
      <address>
        <city>Northampton</city>
        <state>England</state>
        <zip>NN1 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine M. Elwell, MD</last_name>
      <phone>44-1604-54-5246</phone>
      <email>christine.elwell@ngh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon J.S. Rustin, MD</last_name>
      <phone>44-1923-844-389</phone>
      <email>grustin@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sokal</last_name>
      <phone>44-115-969-1169 ext. 57300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Protheroe, MD</last_name>
      <phone>44-186-522-6183</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Berkshire Cancer Centre at Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <state>England</state>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Rogers, MD</last_name>
      <phone>44-118-987-7688</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert E. Coleman, MD, FRCP</last_name>
      <phone>44-114-226-5213</phone>
      <email>r.e.coleman@sheffield.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert A. Huddart, MD</last_name>
      <phone>44-20-8661-3457</phone>
      <email>robert.huddart@icr.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <state>England</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Parker</last_name>
      <phone>44-1935-384-345</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Cancer Research and Cell Biology at Queen's University Belfast</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 7BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seamus McAleer</last_name>
      <phone>44-28-9032-9241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Hutcheon, MD</last_name>
      <phone>44-1224-892-997</phone>
      <email>andrew.hutcheon@arh.grampian.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff White, MD</last_name>
      <phone>44-141-301-7056</phone>
      <email>jeff.white@northglasgow.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Barber, MD</last_name>
      <phone>44-29-2061-5888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL 18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Champion</last_name>
      <phone>44-1745-534-432</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2007</study_first_submitted>
  <study_first_submitted_qc>December 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>testicular seminoma</keyword>
  <keyword>stage I malignant testicular germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Seminoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

